Jichi Medical University at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Jichi Medical University brings 4 presentations to ESGCT 2026 in Hamburg. Its work covers AAV gene therapy for neurological disease, including WDR45 gene replacement that suppresses neurodegeneration in a mouse model of BPAN. Other work raises AAV yield and full capsid content and uses DNA aptamers for target-specific delivery.
| Organization | ESGCT 2026 Attendance |
|---|---|
Jichi Medical University Shimotsuke, Japan | |
Medical university whose Center for Gene Therapy Research develops AAV gene therapies, including for neurological diseases. | Poster Wed Oct 28 1:30pm–3:30pm Effects of the KRAS (G12D)-selective inhibitor MRTX1133 in ovarian mucinous carcinoma Poster Wed Oct 28 1:30pm–3:30pm Identification of disease-specific molecules and development of gene delivery system using target-specific DNA aptamers Poster Wed Oct 28 1:30pm–3:30pm The insertion of a YY1 binding motif at upstream of Rep/Cap increases the AAV vector yield and full capsids Poster Thu Oct 29 2:00pm–4:00pm AAV-mediated WDR45 gene replacement therapy suppresses neurodegeneration in a murine SENDA/BPAN model |
Instantly find 20 buyers from Jichi Medical University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction